

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT5664474

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
WILMINGTON PHARMATECH	06/19/2019
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	INCYTE CORPORATION
<b>Street Address:</b>	1801 AUGUSTINE CUT-OFF
<b>City:</b>	WILMINGTON
<b>State/Country:</b>	DELAWARE
<b>Postal Code:</b>	19803
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	16402955
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(877)769-7945
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	+1 (212) 641-2296
<b>Email:</b>	apsi@fr.com
<b>Correspondent Name:</b>	JUSTIN E. SEARS
<b>Address Line 1:</b>	FISH & RICHARDSON P.C.
<b>Address Line 2:</b>	P.O.BOX 1022
<b>Address Line 4:</b>	MINNEAPOLIS, MINNESOTA 55440-1022
<b>ATTORNEY DOCKET NUMBER:</b>	20443-0541001
<b>NAME OF SUBMITTER:</b>	NANCY MCCOY
<b>SIGNATURE:</b>	/Nancy McCoy/
<b>DATE SIGNED:</b>	08/12/2019
<b>Total Attachments: 4</b>	
source=Executed WPT to Incyte#page1.tif	
source=Executed WPT to Incyte#page2.tif	
source=Executed WPT to Incyte#page3.tif	
source=Executed WPT to Incyte#page4.tif	

Assignment from Wilmington PharmaTech to Incyte Corporation

ASSIGNMENT

Assignor: Wilmington PharmaTech  
a corporation organized and existing under the laws of Delaware, and having a place  
of business at:  
Pencader Corporate Center  
229A Lake Drive  
Newark, DE 19702

Assignee: Incyte Corporation  
a corporation organized and existing under the laws of  
Delaware, and having a place of business at:  
1801 Augustine Cut-Off  
Wilmington, DE 19803

Country	Application No.	Filing Date	Title
United States	16/402,955	5/3/2019	SOLID FORMS OF AN FGFR INHIBITOR AND PROCESSES FOR PREPARING THE SAME

1. Assignor represents that it is the owner of the patents and patent applications listed above, and of all foreign and domestic patents, patent applications, including continuation-in-part applications, reissues, re-examinations, certificates of invention, and the like that derive priority from, or claim the benefit of the filing date of, the patents and patent applications listed above (the "Patents and Patent Applications") and of all new and useful inventions and improvements that are disclosed in the Patents and Patent Applications (the "Inventions"). The Patents and Patent Applications and the Inventions are collectively referred to as the "Patent Assets."
2. Assignor hereby assigns, and confirms any prior assignment, to Assignee its entire worldwide right, title, and interest in and to the Patent Assets, including the right to file and prosecute, in its own name wherever so permitted by law or in the name of Assignee wherever necessary, patent applications, including corresponding and continuing applications, reissues, re-examinations, certificates of invention, and the like based on any of the Patent Assets, and to claim priority to any of the Patents and Patent Applications pursuant to the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent

Assignment from Wilmington PharmaTech to Incyte Corporation

Convention, and all other treaties of like purposes. Assignor acknowledges receipt of fair and adequate consideration for this Assignment.

3. Assignor shall, when requested by Assignee and at no cost to Assignor, (i) execute or cause to be executed all rightful oaths, assignments, and powers of attorney to Assignee or to agents and legal representatives of Assignee, and all other papers necessary and proper to carry out the intent and purpose of this Assignment, (ii) execute all papers necessary in connection with the Patents and Patent Applications, and any continuing, divisional, reissue, reexamination or other corresponding application thereof or post-grant proceeding relating thereto and to execute any separate assignment in connection with any such application as Assignee may deem necessary or expedient; and (iii) perform all affirmative acts that may be necessary to obtain a grant of a valid patent to Assignee on any of the Inventions.
4. Assignor hereby assigns to Assignee all of Assignor's right, title, and interest in and to any claims, whether known or unknown, suspected or unsuspected, of any nature, including choses in action, that Assignor has or may have against any party for infringement of the Patents and Patent Applications, and acknowledges receipt of fair and adequate consideration for this Assignment.
5. Assignor represents that Assignor has the full right to convey the interests assigned by this Assignment, and that Assignor has not executed and will not execute any agreement in conflict with this Assignment.
6. This Assignment is binding upon and inures to the benefit of the successors and assigns of the parties.

[ASSIGNMENT CONTINUES ON SIGNATURE PAGE]

Assignment from Wilmington PharmaTech to Incyte Corporation

The Assignor hereby executes this Assignment.

Assignor: Wilmington PharmaTech

Signature: SHIN WANG

Date: 06/19/19


Name: SHIN WANG

Title: Business Manager

State of Delaware.

County of DE New Castle

This instrument was acknowledged before me on 6/19/2019  
by Shin Wang



[Signature]  
(Signature of Notarial Officer)

Notary Public  
(Title and Rank)

(My commission expires: 02/26/2022)

Assignment from Wilmington PharmaTech to Incyte Corporation

The Assignee hereby acknowledges and accepts the foregoing assignment.

Assignee: Incyte Corporation

Signature: *[Handwritten Signature]*

Date: 1 Aug 2019

Name: Maria E. Pasquale

Title: Executive Vice President & General Counsel

State of Delaware.


County of New Castle

This instrument was acknowledged before me on 8/1/2019  
by Maria E. Pasquale

*[Handwritten Signature: Phyllis L. Reid]*  
(Signature of Notarial Officer)

*[Handwritten: Notary Public]*  
(Title and Rank)

(My commission expires: 12/11/2022)



23441046.doc

